Company
BIMINI Biotech
- Biotech
- Location:
- Leiden, Netherlands
Description
BIMINI Biotech develops first-in-class small-molecule therapeutics targeting the Wiskott–Aldrich Syndrome protein for oncology and autoimmune disease applications, advancing preclinical agonist and antagonist programs for clinical translation.
BIMINI Biotech is located in the Netherlands ecosystem.
Related
Confo TherapeuticsConfo Therapeutics develops GPCR-directed small-molecule and antibody therapies with proprietary technology that targets class A and B…
Laigo BioLaigo Bio develops SureTACs, bispecific molecules that bind membrane targets and membrane E3 ligases to drive ubiquitin-mediated, lysosomal…
ATXA TherapeuticsATXA Therapeutics develops selective small-molecule thromboxane receptor (TP) antagonists, including lead candidate NTP42, to treat…
SpliceBioSpliceBio builds protein splicing–based genetic medicines and develops therapeutics for diseases caused by mutations in large genes,…
NTrans TechnologiesNTrans Technologies develops a non-viral delivery platform for cell and gene therapies, providing modular delivery solutions for…
Captor TherapeuticsCaptor Therapeutics develops therapeutics using targeted protein degradation (TPD) to address high‑unmet‑need diseases such as cancer and…
ActiTrexxActiTrexx develops therapies based on activated regulatory T cells for autoimmune and autoinflammatory diseases, including ATreg/Actileucel…
Tessellate BioTessellate Bio discovers and develops precision oncology small-molecule medicines based on novel synthetic lethality interactions,…
Trained Therapeutix DiscoveryTrained Therapeutix Discovery develops nanobiologic therapeutics that regulate trained immunity for applications in cancer and organ…